China SXT Pharmaceuticals Inc. (SXTC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, SXTC scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 11 / 20. Per the RQD rating, ROIC is 0% and FCF yield is 0%. The SEC financials show operating losses in each of the three reported years, so the cash engine is currently not producing returns on invested capital.
• Whale 13F Flow: 6 / 20. Per the RQD rating, this pillar reflects institutional accumulation and options positioning. The holders section contains no 13F data, so the score cannot be traced to specific institutional holders in the source data.
• Insider Conviction: 5 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The holders section contains no insider or Congressional trade records, so the low score cannot be traced to specific transactions here.
• Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 1.0 with sector sensitivity noted. Market data shows beta of 1.0, which indicates market-average sensitivity to broad moves, but the rating does not indicate a favorable regime fit.
• Forensic Balance Sheet: 8 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 1/9, and Debt/Equity is 0.5. A Piotroski F of 1 out of 9 signals weak financial-health indicators across the nine tests.

For a prospective investor evaluating the stock today, the rating points to a weak fundamental profile across most pillars. The strongest pillar relative to its maximum is the macro fit score, and even that is below half of its weight. Upside drivers are not evident in the source data; the main drivers of the score are negative cash-flow metrics and weak forensic indicators. The recent news flow includes a registered direct offering, which the headlines flag as carrying significant dilution potential. Valuation cannot be assessed on earnings multiples because P/E and EPS are not available in source data, and the market data shows negative operating and net margins.

China SXT Pharmaceuticals Inc. (SXTC) is listed on NASDAQ and classified under the Industrials sector and Diversified Equities industry, per the profile section. The source data does not describe the company's products, customers, or revenue model. The financials show reported revenue of $1.1M for FY 2025, $1.7M for FY 2024, and $1.9M for FY 2023. Market data shows a gross margin of 21.9%.

Per the SEC financials, revenue declined across the three periods while operating losses widened from $-2.5M in FY 2023 to $-7.1M in FY 2025. Market data shows an operating margin of -60% and a net margin of -60%. Per the Roarable RQD rating, ROIC is 0% and the Altman Z-Score is 2.5, while the Piotroski F-Score is 1 out of 9. The RQD rating reports Debt/Equity of 0.5, though the financials table lists debt as N/A for each period, so the balance sheet posture cannot be fully reconciled from the source data.

Per the recent news section, the most prominent headline reports a $12 Million registered direct offering "With Significant Dilution Potential," which is a risk watch item. Multiple outlets (Yahoo Finance, Stock Titan) report the same $12 Million offering. A Quiver Quantitative item describes a thin-float rebound, tagged as a catalyst. A kalkine.ca item asks why the stock collapsed 88% after an offering. A Moomoo item covers analyst ratings, but the content is not included in the source data. The butterfly supply-chain graph lists supply chain as NONE, with no butterfly links and no proprietary signals.

• What are the company's products, customers, and revenue drivers, given that the source data describes only sector and industry labels?
• What are the terms, size, and share count effects of the $12 Million registered direct offering referenced in the news section?
• What is the cash balance and total debt for each reported period, since the financials table lists both as N/A?
• What drives the 52-week range upper bound of $8376000, which appears inconsistent with a current price of 2.85?
• Why does the market cap of $0.4M reconcile with the Roarable rating's Debt/Equity of 0.5 and the reported revenue scale?